What does Aclaris Therapeutics, Inc. do?
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody…
What is Aclaris Therapeutics, Inc.'s P/E and P/B ratio?
Aclaris Therapeutics, Inc. has a P/E ratio of -6.6 and a P/B ratio of 4.53.
What is Aclaris Therapeutics, Inc.'s debt-to-equity ratio?
Aclaris Therapeutics, Inc. has a debt-to-equity ratio of 0.01.
How much does Aclaris Therapeutics, Inc. owe compared with what it owns?
Aclaris Therapeutics, Inc. owes $0.31 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Aclaris Therapeutics, Inc.'s Positivity rank?
Aclaris Therapeutics, Inc. is ranked #4,860 of 6,775 companies globally and #2,527 of 4,000 in United States on PositoAI, with a Positivity Score of 18,902.
Does Aclaris Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Aclaris Therapeutics, Inc..
Where can I read the latest news about Aclaris Therapeutics, Inc.?
Recent headlines about Aclaris Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Aclaris Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Aclaris Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.